Wuxi AppTec and Pfizer have both contributed as the Yale University-founded cancer drug developer prepares for clinical testing next year.
Simcha Therapeutics, a US-based cancer therapeutics developer spun out of Yale University, has obtained $25m of series A funding from investors including pharmaceutical firm WuXi AppTec’s Corporate Venture Fund.
Pharmaceutical firm Pfizer also contributed funding, as did Connecticut Innovations, the strategic venturing arm of Connecticut state, and venture capital firm Sequoia Capital China.
Founded in 2018, Simcha Therapeutics engineers cytokine molecules as the basis for cancer immunotherapies intended to be more effective than existing treatments.
The company’s lead…
